



3 -17-05

IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Georges et al. Art Unit: 1645
Serial No.: 10/736,889 Examiner: Yao
Date Filed: December 15, 2003 Conf. No. 5738
Docket Nos.: AUR-013US and 112418.147US2 Cust. No.: 23483
Title: VIMENTIN DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (Label No. EV621477494US) under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

3/14/05
Date

Brenda L. Robles
Brenda L. Robles

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith the references on the attached Form PTO-1449. Copies of the cited references are enclosed herewith. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97 (b) (3), before the mailing of a first Office Action on the merits, therefore no fee is due. I hereby state under 37 C.F.R. § 1.97 (e) (1) that the items of information contained in this Information Disclosure Statement were cited in two communications (copies enclosed) from a foreign patent office on counterpart foreign applications not more than three months prior to the filing of this Information Disclosure Statement.


The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be material to patentability. Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents constitute prior art under United States law, Applicants reserve the right to present to the Office relevant facts and law regarding the significance of such documents to the patentability of the claimed invention.

Supplemental Information Disclosure Statement
Appln. No. 10/736,889

It is respectfully requested that the Examiner initial and return a copy of the attached Form PTO-1449 with the next Patent Office communication.


No fees are believed to be due in connection with this submission; however, please charge any fees that might be due to Deposit Account Number 08-0219. If there are any questions, the Examiner is invited to call the undersigned at the telephone number indicated below.

Respectfully submitted,



James T. Olesen, Ph.D.
Reg. No. 46,967

Date: March 16, 2005
WILMER CUTLER PICKERING HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)



Subj For, PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Docket Numbers 112418.147US2 and AUR-013US	Application Number 10/736,889
				Applicant(s) Georges et al.	
Sheet	1		1	Filing Date December 15, 2003	Group Art Unit 1642

U.S. Patent Documents

Examiner Initial	Document Number	Publn. Date mm-dd-yyyy	Name Of Patentee Or Applicant Of Cited Documents	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

Foreign Patent Documents

Examiner Initial	Cite No.	Foreign Patent Document	Publn. Date mm-dd-yyyy	Country	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code-Number-Kind			
		DE 41 12999 A1	10/22/1992	DE	
		WO 02/082076 A2	10/17/2002	WIPO	

Examiner's Initial	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)	
	AA	BICHART, F., et al., "Cytoskeleton Alteration in MCF7R Cells, a Multidrug Resistant Human Breast Cancer Cell Line," <i>Anticancer Research</i> , Vol. 17, pp. 3393-3402.
	AB	Database Pubmed [Online], "Triosephosphate Isomerase," US National Library of Medicine, XP002301823, Bethesda, MD, 5 January 2001.
	AC	LUDWIG, A., et al., "Identification of Differential Expressed Genes in Classical and Atypical Multidrug-resistant Gastric Carcinoma Cells," <i>Anticancer Research</i> , Vol.17, pp. 3213-3222, 1997.
	AD	MORAN E., et al., "Co-expression of MDR-Associated Markers, Including P-170, MRP and LRP and Cytoskeletal Proteins, in Three Resistant Variants of the Human Ovarian Carcinoma Cell Line, OAW42," <i>Eur J. Cancer</i> , Vol. 33, pp. 652-660, 1997.
	AE	SEKIGUCHI, M., et al., "Biological Characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines," <i>Biomed. Pharmacother</i> , Vol. 55, pp.466-474, 2001.
	AF	SWEET, P., et al., "Cyclosporin A and Verapamil Enhancement of Daunorubicin-produced Nucleolar Protein B23 Translocation in Daunorubicin-resistant and -sensitive Human and Murine Tumor Cells," <i>Cancer Research</i> , Vol. 49, pp. 677-680, 1989.
	AG	YANG, W., et al., "Multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice," <i>Vaccine</i> , Vol. 19, pp. 103-113, 2001.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	